EGFR and prostate carcinoma: NSCLC, for instance, frequently involves KRAS mutations and EGFR pathway alterations [11], which may interact differently with statin-induced modulation of signalling pathways compared to prostate cancer, where androgen receptor signalling and lipid metabolism are more prominent [12].